Policy Statement on the Impact of Price Negotiations on Innovation, Healthy Aging and Equity

August 10, 2022

As the CEO of the Global Coalition on Aging (GCOA) and a newly formed cross-sector Alliance for Health Innovation, we write to express our deep concern with the current legislation that allows for price “negotiations” in Medicare – a thinly veiled signal for America’s plunge into price controls that will have a devastating and adverse impact on biopharmaceutical innovation and our nations’ ability to support healthy aging. 

As expressed in the piece, Congress Must Support Innovation, Not Pick Winners and Losers, drug price controls for Medicare sends confusing signals to patients, caregivers, and investors on the importance of medical innovation. 

Confoundingly, it is our Medicare population, the fastest growing segment of patients, that is most dependent on innovation to address diseases from HIV, cancer, and cardiovascular disease to osteoporosis and Alzheimer’s.”

Additionally, the legislation itself is peculiarly at odds with the Administration’s renewed Cancer Moonshot initiative, announced as recently as this year’s 2021 State of the Union Address. In that spirit and to ensure limited adverse impact on such future innovation for the health and wellbeing of older adults and all Americans, GCOA and the Alliance for Health Innovation strongly suggest three policy principles accompany any such final legislation that may result in the next days: 

  1. All Medicare “price negotiations” should take place through the screen of its impact on healthy aging & equity. Those administering and overseeing these “price negotiations” must be required to provide to Congress such impact prior to any implementation. Since Medicare will increasingly become a monopsony purchaser as a consequence of the aging of America’s population in our 21st century, the impact will become ever more profound over time and the ensuing responsibilities to show impact ever greater. Healthy aging and equity are impossible without the innovation itself that will enable such patient and caregiver needs. 
  2. HHS & CMS must demonstrate a commitment to transparency & openness in the process for implementing the “Medicare price negotiation” provision. CMS and its parent agency HHS must demonstrate a full commitment to transparency and openness in how it will undertake such a transformational new set of responsibilities. Such transparency is essential so that patients, caregivers, investors, and scientists involved in the biopharmaceutical process across America have a full ability to reflect and communicate the impact it will have on them. CMS has an obligation to ensure open and full dialogue with the ability to partner across society on the impact. 
  3. The legislation should require a report to Congress on the effects of “price negotiations” on innovation, access & equity. Since the prevalence of the diseases of aging increase as 21st-century longevity rises and the fiscal burden grows as the proportion of America’s old outnumbers its young, the economic and fiscal consequences will only be mitigated with a reliable continued flow of new biopharmaceutical innovation. Therefore, any administration of “Medicare price negotiations” must be accompanied by an analysis of the effects on innovation today and in the future. Moreover, such an impact must be done through a full, open, and transparent process that includes society-wide stakeholder input, understood through the lens of equity and healthy aging goals. 

On behalf of GCOA and the Alliance for Health Innovation, we appreciate the ongoing efforts to improve access and affordability for older adults and all Americans and stand ready to work alongside Congress and the Administration to ensure these principles accompany any such final legislation. 

Sincerely,

Michael W. Hodin, PhD 

CEO 

Click here to download PDF of policy statement.

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Brazil Must Fight Antibiotic Resistance

The threat posed by antimicrobial resistance is urgent and spares no country - including Brazil. According to The Lancet, 63 deaths per 100,000 are associated with AMR in Brazil and Paraguay, a rate that exceeds the average for Latin America and the Caribbean. AMR-associated deaths in Brazil are second only to cardiovascular diseases and cancers.

We Missed 100 Million Adult Vaccines – Here’s How We Get Back on Track

Like other pandemics throughout human history, COVID-19 has caused profound changes that are still rippling through our societies, even as people are understandably eager to move on. In fact, these impacts are all the more dangerous when they are largely ignored or effectively invisible. The decline in adult vaccination may be one of the most significant, as a new report finds that ~100 million doses were missed in 2021 and 2022 alone – reversing global progress towards widespread adult immunisation as a new standard of care in a world of more old than young.

New Analysis Shows Lost Ground on Adult Immunisation During the Pandemic with 100 Million Doses Potentially Missed

New data shared today by GSK, in collaboration with the IQVIA Institute for Human Data Science and the Global Coalition on Aging (GCOA), estimate approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated, based on the global vaccination adoption trends observed from 2013 to 2020, compounding already low adoption rates pre-pandemic.

Going Beyond Applause: The Potential of Caregiving to Unlock Job Opportunities of the Future

Early in the COVID-19 pandemic, the role of caregivers – staff and family who provide care for older and dependent people to carry out activities such as eating or moving - catapulted to the front of our collective conscience. The daily applause for front-line care workers showed a high level of recognition for their incredible work and provided insight into how our health systems must change as our society ages. We need to continue to recognise caregivers as essential to our ageing society.

High-Level Forum on the Silver Economy 2023

Join us for the High-Level Forum on the Silver Economy 2023. Now in its fourth year, the Silver Economy Forum 2023, December 6 and 7, will explore aging at every stage of life, looking at the growing global Silver Economy through a multigenerational lens. Linking to the goals and aspirations of the UN Decade of Healthy Ageing, SEF 2023 will highlight key themes at the intersection of aging at every age, and the Silver Economy.

Global Coalition on Aging Workshop Calls on G7 Countries to Fund Pull Incentives to Spur Antibiotic Innovation

The Global Coalition on Aging, in partnership with JPMA, today announced the release of its workshop report on the AMR crisis facing G7 countries and the world, “The Value of Pull Incentives in Japan to Encourage Investment in Antibiotic Innovation to Solve the AMR Crisis.” If strong action is not taken to address AMR, we will lose the antibiotics we need to cure infections, which is likely to outpace cancer as a major cause of death, killing an estimated 10 million by 2050.